{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:23:40Z","timestamp":1781731420087,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40256-021-00519-0","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T01:02:22Z","timestamp":1642467742000},"page":"417-424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A Multicenter Retrospective Evaluation of Direct Oral Anticoagulants for the Treatment of Heparin-Induced Thrombocytopenia"],"prefix":"10.1007","volume":"22","author":[{"given":"Kyle","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Sebaaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Wooten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Khouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Mihm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1370-4694","authenticated-orcid":false,"given":"Sarah A.","family":"Nisly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"519_CR1","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1160\/TH16-01-0074","volume":"116","author":"S Khandelwal","year":"2016","unstructured":"Khandelwal S, Arepally GM. Immune pathogenesis of heparin-induced thrombocytopenia. Thromb Haemost. 2016;116:792\u20138.","journal-title":"Thromb Haemost"},{"key":"519_CR2","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1182\/asheducation-2013.1.668","volume":"2013","author":"GM Lee","year":"2013","unstructured":"Lee GM, Arepally GM. Heparin-induced thrombocytopenia. Hematol Am Soc Hematol Educ Program. 2013;2013:668\u201374.","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"519_CR3","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","volume":"2","author":"A Cuker","year":"2018","unstructured":"Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2:3360\u201392.","journal-title":"Blood Adv"},{"key":"519_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1592\/phco.26.4.461","volume":"26","author":"CH Dang","year":"2006","unstructured":"Dang CH, Durkalski VL, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2006;26:461\u20138.","journal-title":"Pharmacotherapy"},{"key":"519_CR5","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1592\/phco.30.12.1229","volume":"30","author":"LP Skrupky","year":"2010","unstructured":"Skrupky LP, Smith JR, Deal EN, Arnold H, Hollands JM, Martinez EJ, et al. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia. Pharmacotherapy. 2010;30:1229\u201338.","journal-title":"Pharmacotherapy"},{"key":"519_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/ajh.26194","volume":"96","author":"H Nilius","year":"2021","unstructured":"Nilius H, Kaufmann J, Cuker A, Nagler M. Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia. Am J Hematol. 2021;96:805\u201315.","journal-title":"Am J Hematol"},{"key":"519_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1517\/14740338.2013.823946","volume":"13","author":"TE Warkentin","year":"2014","unstructured":"Warkentin TE. Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. Expert Opin Drug Saf. 2014;13:25\u201343.","journal-title":"Expert Opin Drug Saf"},{"key":"519_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/107602960501100306","volume":"11","author":"MJ Hursting","year":"2005","unstructured":"Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Off J Int Acad Clin Appl Thromb. 2005;11:279\u201387.","journal-title":"Clin Appl Thromb Off J Int Acad Clin Appl Thromb."},{"key":"519_CR9","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1182\/blood-2014-09-599498","volume":"125","author":"M Kang","year":"2015","unstructured":"Kang M, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langner A. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015;125:924\u20139.","journal-title":"Blood"},{"key":"519_CR10","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1177\/1060028015579424","volume":"49","author":"MA Miyares","year":"2015","unstructured":"Miyares MA, Davis KA. Direct-acting oral anticoagulants as emerging treatment options for heparin-induced thrombocytopenia. Ann Pharmacother. 2015;49:735\u20139.","journal-title":"Ann Pharmacother"},{"key":"519_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.12659\/AJCR.914575","volume":"20","author":"P Ramachandran","year":"2019","unstructured":"Ramachandran P, Farag F, Morcus R, Gotlieb V. Autoimmune heparin-induced thrombocytopenia: treatment obstacles and challenging length of stay. Am J Case Rep. 2019;20:310\u20133.","journal-title":"Am J Case Rep."},{"key":"519_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1365-2141.2008.07300.x","volume":"143","author":"JM Walenga","year":"2008","unstructured":"Walenga JM, Prechel M, Jeske WP, Hoppensteadt D, Maddineni J, Iqbal O, et al. Rivaroxaban\u2013an oral, direct Factor Xa inhibitor\u2013has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol. 2008;143:92\u20139.","journal-title":"Br J Haematol"},{"key":"519_CR13","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood-2011-05-353391","volume":"119","author":"K Krauel","year":"2012","unstructured":"Krauel K, Hackbarth C, F\u00fcrll B, Greinacher A. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4\/heparin antibodies. Blood. 2012;119:1248\u201355.","journal-title":"Blood"},{"key":"519_CR14","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/ajh.23248","volume":"87","author":"J McFarland","year":"2012","unstructured":"McFarland J, Lochowicz A, Aster R, Chappell B, Curtis B. Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia. Am J Hematol. 2012;87:776\u201381.","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"519_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/ijlh.12993","volume":"41","author":"TE Warkentin","year":"2019","unstructured":"Warkentin TE. Laboratory diagnosis of heparin-induced thrombocytopenia. Int J Lab Hematol. 2019;41(Suppl 1):15\u201325.","journal-title":"Int J Lab Hematol"},{"key":"519_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1182\/blood.V67.1.27.27","volume":"67","author":"D Sheridan","year":"1986","unstructured":"Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67:27\u201330.","journal-title":"Blood"},{"key":"519_CR17","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1001\/archinte.163.15.1849","volume":"163","author":"BE Lewis","year":"2003","unstructured":"Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG, Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163:1849\u201356.","journal-title":"Arch Intern Med"},{"key":"519_CR18","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood-2017-04-778993","volume":"130","author":"TE Warkentin","year":"2017","unstructured":"Warkentin TE, Pai M, Linkins L-A. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood. 2017;130:1104\u201313.","journal-title":"Blood"},{"key":"519_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost JTH. 2005;3:692\u20134.","journal-title":"J Thromb Haemost JTH."},{"key":"519_CR20","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost JTH. 2015;13:2119\u201326.","journal-title":"J Thromb Haemost JTH."},{"key":"519_CR21","doi-asserted-by":"publisher","first-page":"340S","DOI":"10.1378\/chest.08-0677","volume":"133","author":"TE Warkentin","year":"2008","unstructured":"Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:340S-380S.","journal-title":"Chest"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-021-00519-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-021-00519-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-021-00519-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T04:33:38Z","timestamp":1657254818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-021-00519-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["519"],"URL":"https:\/\/doi.org\/10.1007\/s40256-021-00519-0","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"8 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kyle Davis, Jamie Sebaaly, Leslie Wooten, Courtney Khouli, Alexandra Mihm, and Sarah Nisly have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"KD, SN, and AM contributed to study conception and design. KD, JS, LW, CK, AM, and SN contributed to material preparation and data collection. SN analyzed the data. KD, AM, and SN wrote the first draft of the manuscript, and all authors commented on all versions of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}